PCDH19 Clustering Epilepsy

PCDH19 clustering epilepsy (PCDH19-CE) is an X-linked epilepsy and neurodevelopmental disorder caused by pathogenic variants in PCDH19. Its hallmark is recurrent clusters of seizures beginning in early childhood, often triggered by fever.

The inheritance pattern is unusual: heterozygous females are most commonly affected, while many hemizygous males carrying the same variant are unaffected. Mosaic males can be affected.

Why the inheritance pattern is unusual

The leading explanation is cellular interference.

In affected females, random X-chromosome inactivation creates a mixture of cells expressing normal PCDH19 and cells expressing the altered form. The abnormal interaction between these cell populations appears to disrupt brain-network development.

Males

A male whose cells all carry the same PCDH19 variant may have no epilepsy because there is no mixture of normal and abnormal cell populations.

Mosaic males, who have a mixture of variant and non-variant cells, can develop the disorder.

Age at onset

Seizures usually begin before age 3 years, often in infancy.

Fever is a common trigger, especially early in the course.

Seizure clusters

A defining feature is clustering: multiple brief seizures may occur over hours or days.

Clusters can recur repeatedly and may require rescue medication or hospital treatment.

Seizure types

Focal seizures are common, including seizures with impaired awareness, autonomic symptoms or motor features.

Bilateral tonic-clonic seizures and other seizure types can also occur.

Development and behaviour

Intellectual disability ranges from none to severe.

Autism spectrum features, attention difficulties, anxiety, obsessive-compulsive features and behavioural dysregulation are reported more often than in the general population.

EEG and MRI

EEG findings vary and can be focal, multifocal or generalised.

Brain MRI is usually normal or non-specific.

Treatment challenges

PCDH19-CE can be drug resistant, and high-quality comparative treatment trials are limited.

Treatment commonly requires several strategies over time.

Antiseizure medicines

A 2025 systematic review found the most consistent reported seizure reduction with levetiracetam, followed by clobazam and potassium bromide, although evidence quality remains limited and responses vary.

Carbamazepine has often been ineffective or associated with worsening in published series.

Ganaxolone

Ganaxolone has been studied because neurosteroid biology may be altered in PCDH19-CE.

A placebo-controlled phase 2 study showed a larger median seizure reduction with ganaxolone than placebo, but the difference did not reach statistical significance. It should therefore be described as promising rather than proven standard therapy for PCDH19-CE.

Other treatments

Ketogenic dietary therapy, vagus nerve stimulation, corticosteroids and other medicines have been tried with variable results.

Evidence is mostly observational.

Why fever plans matter

Because fever commonly precipitates clusters, families often need an individual plan for rescue medication and thresholds for urgent medical care.

Routine fever management does not guarantee prevention of seizures.

Genetic counselling

The unusual X-linked inheritance can be difficult to explain because affected females and unaffected transmitting males can occur in the same family.

Mosaicism also complicates recurrence-risk assessment.

Worldwide access

Genetic diagnosis is important because the unusual inheritance pattern may otherwise be missed.

Access to testing, rescue medicines, potassium bromide and specialist behavioural support varies substantially between countries.

The central point

PCDH19 clustering epilepsy is defined as much by seizure clustering and its unusual cellular-interference genetics as by any single seizure type.

Sources

Medical note: PCDH19 treatment evidence is limited and highly individual. Rescue planning is especially important for seizure clusters.

Evidence checked: September 2026.